![Page 1: EnprEMA Working Group 4 - European Medicines Agency · and EU Commissions Guideline on Ethics for Pediatric Trials (2008) VI. Risk lists for ECs with practical examples for; Minimal](https://reader033.vdocument.in/reader033/viewer/2022050514/5f9df7bb6d3cd446f777790d/html5/thumbnails/1.jpg)
EnprEMA Working Group 4
Dialogue and Interaction with Ethics Committees
![Page 2: EnprEMA Working Group 4 - European Medicines Agency · and EU Commissions Guideline on Ethics for Pediatric Trials (2008) VI. Risk lists for ECs with practical examples for; Minimal](https://reader033.vdocument.in/reader033/viewer/2022050514/5f9df7bb6d3cd446f777790d/html5/thumbnails/2.jpg)
WG4 Participants
• Allison Needham (SickKids/GRIP) – Chair • Pirkko Lepola(FINPEDMED) • Peter Sallabank (Regulinx) • Jo Mendum (PRA International) • David Neubauer (European Academy of
Pediatrics/Ljubljana University) • Ivana Silva (EMA) • Richard Trompeter (GOSH/ IPTA) • Alan Boddy (Newcastle University)
![Page 3: EnprEMA Working Group 4 - European Medicines Agency · and EU Commissions Guideline on Ethics for Pediatric Trials (2008) VI. Risk lists for ECs with practical examples for; Minimal](https://reader033.vdocument.in/reader033/viewer/2022050514/5f9df7bb6d3cd446f777790d/html5/thumbnails/3.jpg)
Agreed activities for WG Report Preparation
1) Compile a list of the problems in attaining ethics approval for multi centered trials across jurisdictions and countries.
2) Find examples of good practice (ethics boards that are on the right track towards efficient and consist ethics approval)
3) List recommendations for practice informed by the EC’s outlined in number 2
![Page 4: EnprEMA Working Group 4 - European Medicines Agency · and EU Commissions Guideline on Ethics for Pediatric Trials (2008) VI. Risk lists for ECs with practical examples for; Minimal](https://reader033.vdocument.in/reader033/viewer/2022050514/5f9df7bb6d3cd446f777790d/html5/thumbnails/4.jpg)
EC Issues Summarized
General EC Issues: • Overall the approval process is complex, costly,
heterogeneous, and time consuming • Variation in informed recruitment and consent
regulations • Vast difference in the interpretation and
implementation of core regulatory documents • The data requirements for submission vary
between ECs
![Page 5: EnprEMA Working Group 4 - European Medicines Agency · and EU Commissions Guideline on Ethics for Pediatric Trials (2008) VI. Risk lists for ECs with practical examples for; Minimal](https://reader033.vdocument.in/reader033/viewer/2022050514/5f9df7bb6d3cd446f777790d/html5/thumbnails/5.jpg)
EC Issues Summarized
Pediatrics specific concerns: • National requirements for ICFs are varied
– Age ranges for providing assent and consent – Parental requirements for providing consent (ie 1
parent vs two parent signatures).
• Justification for appropriate age grouping • Age appropriate test procedures for children
i.e. minimizing blood draw frequencies
![Page 6: EnprEMA Working Group 4 - European Medicines Agency · and EU Commissions Guideline on Ethics for Pediatric Trials (2008) VI. Risk lists for ECs with practical examples for; Minimal](https://reader033.vdocument.in/reader033/viewer/2022050514/5f9df7bb6d3cd446f777790d/html5/thumbnails/6.jpg)
![Page 7: EnprEMA Working Group 4 - European Medicines Agency · and EU Commissions Guideline on Ethics for Pediatric Trials (2008) VI. Risk lists for ECs with practical examples for; Minimal](https://reader033.vdocument.in/reader033/viewer/2022050514/5f9df7bb6d3cd446f777790d/html5/thumbnails/7.jpg)
External problems (1) Internal problems (2)
![Page 8: EnprEMA Working Group 4 - European Medicines Agency · and EU Commissions Guideline on Ethics for Pediatric Trials (2008) VI. Risk lists for ECs with practical examples for; Minimal](https://reader033.vdocument.in/reader033/viewer/2022050514/5f9df7bb6d3cd446f777790d/html5/thumbnails/8.jpg)
Solutions for these problems
![Page 9: EnprEMA Working Group 4 - European Medicines Agency · and EU Commissions Guideline on Ethics for Pediatric Trials (2008) VI. Risk lists for ECs with practical examples for; Minimal](https://reader033.vdocument.in/reader033/viewer/2022050514/5f9df7bb6d3cd446f777790d/html5/thumbnails/9.jpg)
Short Term Proposal (≤6 months)
I. Check lists of EC submission documents for both applicants (sponsors, investigators) and ECs
II. Training program structure for EC members; increasing knowledge and competency for pediatric trials
III. Guideline with good existing examples to support communication between ECs; meetings and information exchange – how it could be done
IV. Draft of Standardized meeting processes (local /national) V. Draft of Standardized evaluating processes (local / national) – based
on ICH Guideline E11 for Clinical Trials of Pediatric Population (2000) and EU Commissions Guideline on Ethics for Pediatric Trials (2008)
VI. Risk lists for ECs with practical examples for; Minimal risks, Low risks and High risks to be used for evaluation of trial risk levels and benefits and possible long term effects (health) for the participant (e.g. need for different IC procedures, like both parents consent procedure instead of normal one, or minors independent IC)
![Page 10: EnprEMA Working Group 4 - European Medicines Agency · and EU Commissions Guideline on Ethics for Pediatric Trials (2008) VI. Risk lists for ECs with practical examples for; Minimal](https://reader033.vdocument.in/reader033/viewer/2022050514/5f9df7bb6d3cd446f777790d/html5/thumbnails/10.jpg)
Long Term Proposal (1-10 years)
I. Create infrastructure needed for harmonised EC practice including electronic data capture systems, forums for common document access and training material
II. “An EC Tool kit” for Pharma Industry; can be used immediately (includes table of differences between every EU Member State / Country)-example incl.
III. Creating new “GEP-Ped; Good Ethical Practice for Pediatric Studies” -guideline
IV. Political discussions to be started V. Discussions between Competent Authorities to be
started
![Page 11: EnprEMA Working Group 4 - European Medicines Agency · and EU Commissions Guideline on Ethics for Pediatric Trials (2008) VI. Risk lists for ECs with practical examples for; Minimal](https://reader033.vdocument.in/reader033/viewer/2022050514/5f9df7bb6d3cd446f777790d/html5/thumbnails/11.jpg)
Who will be responsible for these deliverables and tasks?
What are the available resources?
![Page 12: EnprEMA Working Group 4 - European Medicines Agency · and EU Commissions Guideline on Ethics for Pediatric Trials (2008) VI. Risk lists for ECs with practical examples for; Minimal](https://reader033.vdocument.in/reader033/viewer/2022050514/5f9df7bb6d3cd446f777790d/html5/thumbnails/12.jpg)